AGP Executive Report
Last update: 9 hours agoClinical Trials & Pharma R&D: Recce Pharmaceuticals won ethics approval to expand its RECCE® 327 topical gel Phase 3 program for diabetic foot infections, widening eligibility to moderate cases and adding ulcer-level endpoints. Regulation & Accountability: In the Philippines’ Pharmally graft case, a COA officer submitted additional documents tied to alleged anomalies in COVID-19 medical fund transfers. Biotech Partnerships: BioArctic and Eli Lilly struck a deal using BrainTransporter™ tech, with $30M upfront and up to $770M in milestones. Public Health Threats: Ebola in DR Congo has topped 1,000 cases, with health workers falling ill and dying amid weak infection control and PPE shortages. Healthcare Access & Ops: Heallexa says US appointment waits are worsening because patients can’t find open slots, and it’s indexing millions of providers for faster booking. Addiction Safety: UK ketamine use is up sharply, and clinics warn of “ketamine bladder” and lasting damage. Food & Consumer Safety: India’s consumer watchdog fined brands over “100%” health/ingredient claims and ordered withdrawals. Tech for Care: PurpleLab launched an identity resolution tool to connect de-identified patient and HCP data across partners in privacy-preserving setups.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
